This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
by Zacks Equity Research
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
NVSPositive Net Change RHHBYPositive Net Change KRYSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
GILDPositive Net Change ABBVPositive Net Change KRYSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay
by Zacks Equity Research
The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.
RMDNegative Net Change TFXPositive Net Change MEDPPositive Net Change HIMSNegative Net Change
medical
Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M
by Zacks Equity Research
Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change SRDXNegative Net Change
medical medical-devices
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
by Zacks Equity Research
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
RMDNegative Net Change BLFSNegative Net Change MEDPPositive Net Change HIMSNegative Net Change
medical
The Zacks Analyst Blog Highlights JPMorganChase, Chevron, Cisco Systems, Atrion and The Eastern
by Zacks Equity Research
JPMorganChase, Chevron, Cisco Systems, Atrion and The Eastern are part of the Zacks top Analyst Blog.
JPMPositive Net Change CVXPositive Net Change CSCOPositive Net Change EMLNegative Net Change ATRINegative Net Change
computers finance industrial-products medical oil-energy
Charles River (CRL) Launches Viral Vector Tech Transfer Program
by Zacks Equity Research
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
RMDNegative Net Change CRLNegative Net Change MEDPPositive Net Change HIMSNegative Net Change
medical medical-devices
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
RAREPositive Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
DaVita (DVA) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in kidney care.
BSXPositive Net Change ECLPositive Net Change DVANegative Net Change HQYPositive Net Change
medical medical-devices
Best Momentum Stocks to Buy for May 31st
by Zacks Equity Research
MNSO, LNTH and LXFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 31, 2023.
LXFRPositive Net Change LNTHPositive Net Change MNSONegative Net Change
medical
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.
BSXPositive Net Change ALGNPositive Net Change RMDNegative Net Change VEEVNegative Net Change
earnings medical medical-devices
QIAGEN (QGEN) Develops Test for Research and CDx Application
by Zacks Equity Research
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
RMDNegative Net Change MYGNPositive Net Change QGENPositive Net Change MEDPPositive Net Change
medical medical-devices
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
by Zacks Equity Research
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
REGNPositive Net Change SNYPositive Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.
RMDNegative Net Change GMEDPositive Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
Watch These 5 Stocks That Recently Hiked Dividends
by Santanu Roy
Investors may keep a tab on stocks like HLNE, RL, SPTN, EQH and MDT, which have lately hiked their dividend payments.
MDTPositive Net Change RLPositive Net Change SPTNNegative Net Change HLNEPositive Net Change EQHNegative Net Change
consumer-discretionary finance medical retail
Zacks.com featured highlights include BellRing Brands, Paylocity, Transdigm and NVIDIA
by Zacks Equity Research
BellRing Brands, Paylocity, Transdigm and NVIDIA are part of the Zacks Screen of the Week article.
NVDANegative Net Change TDGPositive Net Change PCTYNegative Net Change BRBRPositive Net Change
aerospace computers medical semiconductor
Is The Options Market Predicting A Spike In Integra LifeScience (IART) Stock?
by Zacks Equity Research
Investors need to pay close attention to Integra LifeScience (IART) stock based on the movements in the options market lately.
IARTPositive Net Change
medical medical-devices
Compelling Reasons to Hold on to Ensign Group (ENSG) Stock
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, an expanding healthcare portfolio and solid cash reserves.
ALCPositive Net Change THCPositive Net Change LMATPositive Net Change ENSGPositive Net Change
medical
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
by Zacks Equity Research
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
JNJPositive Net Change HRTXPositive Net Change MRNSNegative Net Change ARQTNegative Net Change
biotechs medical
Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success
by Zacks Equity Research
Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.
RMDNegative Net Change ZBHPositive Net Change MEDPPositive Net Change EHCPositive Net Change
medical medical-devices
SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon
by Zacks Equity Research
SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.
AMZNNegative Net Change MEDPPositive Net Change SNESPositive Net Change HIMSNegative Net Change
medical
Tenet Healthcare (THC) Gains 89% in a Year: More Room to Run?
by Zacks Equity Research
Tenet Healthcare (THC) is well-poised to gain from improved volumes, expansion of specialty services, streamlining operations and operational efficiency.
THCPositive Net Change LNTHPositive Net Change PNTGPositive Net Change OGNPositive Net Change
medical
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
BSXPositive Net Change ECLPositive Net Change ALGNPositive Net Change LNTHPositive Net Change
medical medical-devices
Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe
by Zacks Equity Research
Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.
BSXPositive Net Change ECLPositive Net Change SYKPositive Net Change ALGNPositive Net Change
medical medical-devices
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
DVANegative Net Change ALGNPositive Net Change EHCPositive Net Change RVTYPositive Net Change
medical medical-devices